Pcv100 the Relationship Between High Density Lipoprotein Cholesterol (Hdl-C), Nicotinic Acid and All-Cause Mortality

An Economic Evaluation of Colesevelam when Added to Metformin-, Insulin- or Sulfonylurea-Based Therapies in Patients with Uncontrolled Type 2 Diabetes Mellitus

“…Since most patients with T2DM also have hypercholesterolaemia that is not at the recommended low-density lipoprotein cholesterol (LDL-C) goal and colesevelam also improves LDL-C, non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein (apo)-B levels, [21][22][23] the DRE is coupled with the 'LIPID cardiovascular risk equation' (LCRE), which translates improved lipid levels with reductions in cardiovascular events. [24,25] Thus, this study evaluates the economic benefits (cost savings) associated with the addition of colesevelam to metformin-, insulin-and sulfonylureabased diabetic treatment regimens in patients who had yet to achieve glycaemic control. The analysis is conducted from the perspective of US managed care organizations.…”